{"id":775761,"date":"2023-08-07T06:03:54","date_gmt":"2023-08-07T10:03:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/"},"modified":"2023-08-07T06:03:54","modified_gmt":"2023-08-07T10:03:54","slug":"biontech-announces-second-quarter-2023-financial-results-and-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/","title":{"rendered":"BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>\n          <i>Significant pipeline advancement highlighted by the initiation of BNT316\/ONC-392 Phase 3 pivotal trial and multiple trials planned to start across the oncology portfolio<\/i>\n        <\/li>\n<li>\n          <i>Positive data updates across multiple technology platforms including ADC candidate BNT323\/DB-1303, anti-CTLA4 monoclonal antibody candidate BNT316\/ONC-392 and CAR-T candidate BNT211 <\/i>\n        <\/li>\n<li>\n          <i>Preparation for launch of Omicron XBB.1.5-adapted monovalent COVID-19 vaccine as recommended by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and other health authorities; deliveries expected to start as early as September, subject to regulatory approval<\/i>\n        <\/li>\n<li>\n          <i>Reiterates COVID-19 vaccine revenue guidance of approximately \u20ac5 billion in 2023<\/i>\n        <\/li>\n<li>\n          <i>First half<sup>1<\/sup> of 2023 revenues of \u20ac1.4\u00a0billion<sup>2<\/sup>, net profit of \u20ac311.8 million and fully diluted earnings per share of \u20ac1.28 ($1.38<sup>3<\/sup>)<\/i>\n        <\/li>\n<\/ul>\n<p align=\"center\">\n        <b>Conference call and webcast scheduled for August 7, 2023, at 8:00 am EDT (2:00 pm CEST)<\/b>\n      <\/p>\n<p align=\"justify\">\n        <b>MAINZ, Germany, August 7, 2023 (GLOBE NEWSWIRE)<\/b> &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T3lkCT8gqodV6zphavSt1B5gWkIMQ-48NAEoimElty-vxc4xGk5rzBGTpJnU34bQcG93gd_Z5cVmex_a_WfbwSpyGRUK82SnSvQleIpn468=\" rel=\"nofollow noopener\" target=\"_blank\"><u>BioNTech SE<\/u><\/a> (Nasdaq: BNTX, \u201cBioNTech\u201d or \u201cthe Company\u201d) today reported financial results for the three and six months ended June 30, 2023, and provided an update on its corporate progress.<\/p>\n<p align=\"justify\">\u201cWe are progressing our oncology pipeline into late-stage development, having launched a pivotal Phase 3 trial and preparing for additional trials with registrational potential in the coming months,\u201d <b>said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech<\/b>. \u201cSimultaneously, we are enhancing our infectious disease pipeline to address global health needs and are developing an Omicron XBB.1.5-adapted monovalent COVID-19 vaccine to become available for the upcoming fall-winter season, subject to regulatory approvals.\u201d <\/p>\n<p align=\"justify\">\n        <b>Financial Review for the Second Quarter and First Half of 2023<\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:131px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    in millions \u20ac, except per share data    <\/td>\n<td style=\"width:108px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>Second Quarter 2023<\/b>\n          <\/td>\n<td style=\"width:116px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">\n            <b>Second Quarter 2022<\/b>\n          <\/td>\n<td style=\"width:125px;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom;text-align: center;vertical-align: middle\">\n            <b>First Half <\/b><br \/>\n            <br \/>\n            <b>2023<\/b>\n          <\/td>\n<td style=\"width:121px;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom;text-align: center;vertical-align: middle\">\n            <b>First Half <\/b><br \/>\n            <br \/>\n            <b>2022<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:131px;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    Total Revenues<sup>2<\/sup><\/td>\n<td style=\"width:108px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    167.7    <\/td>\n<td style=\"width:116px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    3,196.5    <\/td>\n<td style=\"width:125px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    1,444.7    <\/td>\n<td style=\"width:121px;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    9,571.1    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:131px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    Net Profit \/ (Loss)    <\/td>\n<td style=\"width:108px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (190.4)    <\/td>\n<td style=\"width:116px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    1,672.0    <\/td>\n<td style=\"width:125px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    311.8    <\/td>\n<td style=\"width:121px;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    5,370.8    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:131px;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    Diluted Earnings \/ (Loss) per Share    <\/td>\n<td style=\"width:108px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (0.79)    <\/td>\n<td style=\"width:116px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    6.45    <\/td>\n<td style=\"width:125px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    1.28    <\/td>\n<td style=\"width:121px;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    20.69    <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <b>Total revenues<\/b> reported were \u20ac167.7 million<sup>2<\/sup> for the three months ended June\u00a030, 2023, compared to \u20ac3,196.5\u00a0million for the comparative prior year period. For the six months ended June\u00a030, 2023, total revenues were \u20ac1,444.7 million<sup>2<\/sup>, compared to \u20ac9,571.1 million for the comparative prior year period. Write-offs by BioNTech\u2019s collaboration partner Pfizer, Inc. (\u201cPfizer\u201d) significantly reduced the Company\u2019s gross profit share in the second quarter and hence negatively influenced its revenues for the three months ended June 30, 2023.<\/p>\n<p align=\"justify\">\n        <b>Cost of sales<\/b> were \u20ac162.9 million for the three months ended June\u00a030, 2023, compared to \u20ac764.6\u00a0million for the comparative prior year period. For the six months ended June\u00a030, 2023, cost of sales were \u20ac258.9 million, compared to \u20ac2,058.7 million for the comparative prior year period. The change was in line with decreasing COVID-19 vaccine sales.<\/p>\n<p align=\"justify\">\n        <b>Research and development<\/b> expenses were \u20ac373.4 million for the three months ended June\u00a030, 2023, compared to \u20ac399.6 million for the comparative prior year period. For the six months ended June\u00a030, 2023, research and development expenses were \u20ac707.4 million, compared to \u20ac685.4\u00a0million for the comparative prior year period. Research and Development (R&amp;D) expenses are mainly influenced by progressing clinical studies for pipeline candidates, the development of variant adapted as well as next generation COVID-19 vaccines and expanding R&amp;D headcount. <\/p>\n<p align=\"justify\">\n        <b>General and administrative<\/b> expenses were \u20ac122.7 million for the three months ended June\u00a030, 2023, compared to \u20ac130.0 million for the comparative prior year period. For the six months ended June\u00a030, 2023, general and administrative expenses were \u20ac242.1 million, compared to \u20ac220.8\u00a0million for the comparative prior year period. G&amp;A expenses were mainly influenced by increased expenses for IT services as well as expanding the G&amp;A headcount. <\/p>\n<p align=\"justify\">\n        <b>Income taxes<\/b> were realized with an amount of \u20ac221.8 million tax income for the three months ended June\u00a030, 2023, compared to \u20ac647.3 million of tax expenses accrued for the comparative prior year period. For the six months ended June\u00a030, 2023, income taxes were realized with an amount of \u20ac16.3\u00a0million tax income, compared to \u20ac1,966.6 million tax expenses accrued for the comparative prior year period. The derived annual effective income tax rate for the six months ended June\u00a030, 2023, was minus 5.5% which is expected to change over the 2023 financial year to be in line with the updated estimated annual cash effective income tax rate of somewhere around 21% for the BioNTech Group.<\/p>\n<p align=\"justify\">\n        <b>Net loss<\/b> was \u20ac190.4 million for the three months ended June\u00a030, 2023, compared to \u20ac1,672.0\u00a0million net profit for the comparative prior year period. For the six months ended June\u00a030, 2023, <b>net profit <\/b>was \u20ac311.8 million, compared to \u20ac5,370.8 million net profit for the comparative prior year period.<\/p>\n<p align=\"justify\">\n        <b>Cash and cash equivalents as well as security investments<\/b> were \u20ac14,166.6 million as well as \u20ac2,667.0\u00a0million, respectively, as of June 30, 2023. Subsequent to the end of the reporting period, the payment settling BioNTech\u2019s gross profit share for the first quarter of 2023 (as defined by the contract with Pfizer) in the amount of \u20ac1,059.2\u00a0million was received from BioNTech&#8217;s collaboration partner as of July\u00a017, 2023. In addition, until early August 2023, \u20ac437.7\u00a0million was received in connection with the amended COVID-19 Vaccine Purchase Agreement with the European Commission (EC).<\/p>\n<p align=\"justify\">\n        <b>Loss per share<\/b> was \u20ac0.79 for the three months ended June\u00a030, 2023, compared to a diluted earnings per share \u20ac6.45 for the comparative prior year period. For the six months ended June\u00a030, 2023, diluted <b>earnings per share<\/b> was \u20ac1.28, compared to \u20ac20.69 diluted earnings per share for the comparative prior year period.<\/p>\n<p align=\"justify\">\n        <b>Shares outstanding<\/b> as of June 30, 2023, were 239,771,156, excluding 8,781,044 shares in treasury.<br \/>In March 2023, BioNTech initiated a new share repurchase program pursuant to which the Company may purchase American Depositary Shares, or ADSs, each representing one ordinary share of the Company, in the amount of up to $0.5 billion during the remainder of 2023. During the three months ended June 30, 2023, 1,532,685 American Depositary Shares were repurchased under the share repurchase program of ADSs at an average price of \u20ac100.45 ($108.92<sup>3<\/sup>), for total consideration of \u20ac154.0\u00a0million ($166.9\u00a0million<sup>3<\/sup>).<\/p>\n<p align=\"justify\">\n        <b>Cash outflows and share consideration <\/b>in connection with the acquisition of InstaDeep Ltd. (\u201cInstaDeep\u201d) on July 31, BioNTech invested approximately \u20ac450 million not including potential future milestones.<\/p>\n<p align=\"justify\">\u201cWe enter the second half of 2023 with a strong financial position, on track to launch our new variant-adapted COVID-19 vaccine and to conduct multiple clinical trials with registrational potential across our oncology and infectious disease pipeline. The COVID-19 vaccine market remains highly dynamic and difficult to fully predict. Along with our partner Pfizer, the Company continues to focus on supporting successful vaccinations during the autumn respiratory infection season,\u201d <b>said Jens Holstein, CFO of BioNTech. <\/b>\u201dIt is our goal to become a multi-product company by investing in our own clinical programs and by complementing them with additional compounds from our partners. With some uncertainty on the revenue line, we are also carefully watching our spending by revisiting our cost base while remaining focused on executing against our strategic goals and providing value to the public and our shareholders.\u201d<\/p>\n<p align=\"justify\">\n        <b>Outlook for the 2023 Financial Year<\/b><br \/>\n        <br \/>The Company reiterates its COVID-19 vaccine revenue guidance and updates its previous expense and capex guidance for the 2023 financial year:<\/p>\n<p align=\"justify\">\n        <i>BioNTech COVID-19 Vaccine Revenues for the 2023 Financial Year:<\/i>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:473px;text-align: justify;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    Estimated BioNTech COVID-19 vaccine revenues for the full 2023 financial year    <\/td>\n<td style=\"width:128px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    ~ \u20ac5 billion    <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">This estimate reflects expected revenues related to BioNTech\u2019s share of gross profit from COVID-19 vaccine sales in the collaboration partners\u2019 territories, from direct COVID-19 vaccine sales to customers in BioNTech\u2019s territory and expected revenues generated from products manufactured by BioNTech and sold to collaboration partners, which may be influenced by costs such as inventory write-offs once materialized and shared with the collaboration partner Pfizer. <\/p>\n<p align=\"justify\">Revenue guidance is based on various assumptions, including, but not limited to, the expected transition from an advanced purchase agreement environment to commercial market ordering starting in some geographies and an expected regulatory recommendation to adapt the COVID-19 vaccines to address newly circulating variants or sublineages of SARS-CoV-2. While vaccine adaptation is expected to lead to increased demand, fewer primary vaccinations and lowered population-wide levels of boosting are anticipated. In addition, seasonal demand is assumed, moving expected revenue generation to the second half of the year 2023 as previously reported. The revenues guidance reflects the revenues as specified by the amendment of the contractual agreement with the EC on behalf of the member states while it largely remains dependent on revenues generated in BioNTech\u2019s collaboration partner\u2019s territories. The market dynamics for COVID-19 vaccines are influenced by various factors which underlie substantial uncertainties and might affect the demand for COVID-19 vaccines in general as well as the Company\u2019s estimated revenues. <\/p>\n<p align=\"justify\">\n        <i>Planned 2023 Financial Year Expenses and Capex<\/i><br \/>\n        <sup>4<\/sup><br \/>\n        <i>:<\/i>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:275px;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:163px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    Previous Guidance    <\/td>\n<td style=\"width:163px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    Updated Guidance    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:275px;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    R&amp;D expenses<sup>5<\/sup><\/td>\n<td style=\"width:163px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    \u20ac2,400m &#8211; \u20ac2,600m    <\/td>\n<td style=\"width:163px;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    \u20ac2,000m &#8211; \u20ac2,200m    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:275px;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    SG&amp;A expenses    <\/td>\n<td style=\"width:163px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u20ac650m &#8211; \u20ac700m     <\/td>\n<td style=\"width:163px;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u20ac600m &#8211; \u20ac700m     <\/td>\n<\/tr>\n<tr>\n<td style=\"width:275px;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    Capital expenditures for operating activities<sup>6<\/sup><\/td>\n<td style=\"width:163px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u20ac500m &#8211; \u20ac600m     <\/td>\n<td style=\"width:163px;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    \u20ac350m &#8211; \u20ac450m     <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <i>Estimated 2023 Financial Year Tax Assumptions:<\/i>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:276px;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:163px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    Previous Guidance    <\/td>\n<td style=\"width:163px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    Updated Guidance    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:276px;text-align: justify;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">    BioNTech Group estimated annual cash effective income tax rate<sup>7<\/sup><\/td>\n<td style=\"width:163px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    ~ 27%    <\/td>\n<td style=\"width:163px;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: bottom\">    ~ 21%    <\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">The full interim unaudited condensed consolidated financial statements can be found in BioNTech\u2019s Report on Form 6-K, filed today with the United States Securities and Exchange Commission (\u201cSEC\u201d) and available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ylc2lem7k_m7IpN5JQC-C2N1vuosOLVM5O3y5iP1NGWaTeyDhCQ98uCIiANMtx7X-d3mvbKO0JBNOysfG2ZRKE47YVgnSRq1aqLB3Wl3UQ4=\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/www.sec.gov\/<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <b>Endnotes<\/b><br \/>\n        <br \/>\n        <sup>1 <\/sup>Financial information is prepared and presented in Euros and numbers are rounded to millions and billions of Euros in accordance with standard commercial practice.<br \/><sup>2 <\/sup>BioNTech\u2019s profit share is estimated based on preliminary data shared between Pfizer and BioNTech as further described in the Annual Report. Any changes in the estimated share of the collaboration partner\u2019s gross profit will be recognized prospectively.<br \/><sup>3 <\/sup>Calculated applying the average foreign exchange rate for the three and six months ended June\u00a030, 2023, as published by the German Central Bank (Deutsche Bundesbank).<br \/><sup>4 <\/sup>Numbers reflect current base case projections and are calculated based on constant currency rates.<br \/><sup>5 <\/sup>Numbers include effects identified from additional collaborations or potential M&amp;A transactions to the extent disclosed and will be updated as needed.<br \/><sup>6 <\/sup>Numbers exclude potential effects caused by or driven from collaborations or M&amp;A transactions.<br \/><sup>7 <\/sup>Numbers exclude potential effects caused by or driven from share-based payment settlements in the course of 2023.<\/p>\n<p align=\"justify\">\n        <b>Operational Review and Pipeline Update for the Second Quarter 2023 and Key Post Period-End Events<\/b>\n      <\/p>\n<p align=\"justify\">\n        <i>COVID-19 Marketed Products<\/i>\n      <\/p>\n<ul>\n<li>In May, BioNTech and Pfizer announced an agreement with the EC to amend the previous COVID-19 Vaccine Purchase Agreement to deliver COVID-19 vaccines doses to the European Union. The amended agreement reflects BioNTech and Pfizer\u2019s commitment to working collaboratively to help address ongoing public health needs, while respecting the principles of the original agreement. It includes re-phasing of delivery of doses annually through 2026. In addition, the agreement includes an aggregate volume reduction, providing additional flexibility for EU Member States. The EC will maintain access to future adapted COVID-19 vaccines and the ability to donate doses, in alignment with the original agreement.<\/li>\n<li>In June, BioNTech and Pfizer submitted regulatory applications to the EMA and to the U.S. FDA for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine for individuals 6 months of age and older in line with recommendations from both regulatory agencies. Regulatory submissions in other territories have also been initiated.<\/li>\n<li>BioNTech and Pfizer have manufactured Omicron XBB.1.5-adapted monovalent COVID-19 vaccine doses at risk to ensure readiness ahead of the fall and winter seasons in various regions worldwide. The companies plan to prepare shipments of Omicron XBB.1.5-adapted monovalent COVID-19 vaccine doses for fast delivery following potential regulatory approval.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <i>Oncology Pipeline Highlights &#8211; Recent and upcoming trial starts and data readouts<\/i>\n      <\/p>\n<p align=\"justify\">\n        <b>BNT316\/ONC-392 (gotistobart)<\/b> is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4, Inc. (\u201cOncoC4\u201d). BNT316\/ONC-392 offers a potentially differentiated safety profile that may allow for higher dosing and longer duration of treatment both as a monotherapy and in combination with other therapies.<\/p>\n<ul>\n<li>In June, BioNTech and OncoC4 initiated a Phase 3 clinical trial (<a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05671510\" rel=\"nofollow noopener\" target=\"_blank\"><u>NCT05671510<\/u><\/a>) to evaluate BNT316\/ONC-392 as monotherapy in non-small cell lung cancer (NSCLC) patients whose disease progressed on anti-PD-1\/PD-L1 antibody-based therapy. The program received Fast Track Designation from the FDA in 2022.<\/li>\n<li>Data from a dose escalation and an expansion cohort evaluating BNT316\/ONC-392 as monotherapy in NSCLC patients that had progressed on prior immune-checkpoint inhibitor (ICI) therapy as part of the ongoing Phase 1\/2 clinical trial (<a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04140526\" rel=\"nofollow noopener\" target=\"_blank\"><u>NCT04140526<\/u><\/a>) were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2023. BNT316\/ONC-392 was generally well-tolerated with a manageable safety profile. Early readout of the expansion cohort showed encouraging clinical activity in patients with ICI-resistant NSCLC.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>BNT323\/DB-1303 <\/b>is a HER2-targeted antibody-drug conjugate (ADC) candidate, being developed in collaboration with Duality Biologics (Suzhou) Co. Ltd. (\u201cDualityBio\u201d).<\/p>\n<ul>\n<li>BNT323\/DB-1303 is being evaluated in a Phase 1\/2 clinical trial (<a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05150691\" rel=\"nofollow noopener\" target=\"_blank\"><u>NCT05150691<\/u><\/a>) in patients with advanced\/unresectable, recurrent, or metastatic HER2-expressing solid tumors. Data from the ongoing trial were presented at the 2023 ASCO Annual Meeting suggesting that BNT323\/DB-1303 was well tolerated and adverse events (AEs) were manageable. Preliminary antitumor activity was observed in heavily pretreated HER2-expressing patients with a median of seven prior systemic treatment regimens, including other HER2 ADCs.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>BNT324\/DB-1311 <\/b>is a topoisomerase-1 inhibitor-based ADC candidate being developed in collaboration with DualityBio.<\/p>\n<ul>\n<li>A first-in-human, open-label Phase 1\/2 clinical trial evaluating BNT324\/DB-1311 in multiple advanced solid tumors is planned to start this year.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>BNT116 <\/b>is based on BioNTech\u2019s FixVac platform, a wholly owned, systemically administered, off-the-shelf mRNA-based cancer vaccine candidate. This candidate is being evaluated for the treatment of advanced NSCLC.<\/p>\n<ul>\n<li>In July 2023, BioNTech and Regeneron Pharmaceuticals Inc. (\u201cRegeneron\u201d) initiated a randomized, controlled, Phase 2 clinical trial (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05557591?cond=NCT05557591&amp;rank=1\" rel=\"nofollow noopener\" target=\"_blank\"><u>NCT05557591<\/u><\/a>) to evaluate BNT116 in combination with cemiplimab (Regeneron\u2019s Libtayo) and cemiplimab alone as first-line treatment of patients with advanced NSCLC whose tumors express PD-L1 in \u2265 50% of tumor cells.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>BNT122 (Autogene cevumeran) <\/b>is an mRNA cancer vaccine candidate based on an individualized neoantigen-specific immunotherapy (iNeST) approach being developed in collaboration with Genentech, a member of the Roche Group (\u201dRoche\u201d).<\/p>\n<ul>\n<li>A randomized Phase 2 clinical trial (<a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05968326?term=GO44479&amp;draw=2&amp;rank=1\" rel=\"nofollow noopener\" target=\"_blank\"><u>NCT05968326<\/u><\/a>) is planned to start in 2H 2023 to further evaluate the safety and efficacy of BNT122 in the adjuvant setting in combination with atezolizumab (Genentech\u2019s Tecentriq) followed by chemotherapy in patients with resected pancreatic ductal adenocarcinoma (PDAC) supported by data from an investigator-initiated Phase 1 trial (<a href=\"https:\/\/classic.clinicaltrials.gov\/show\/NCT04161755\" rel=\"nofollow noopener\" target=\"_blank\"><u>NCT04161755<\/u><\/a>). In May 2023, results from the Phase 1 trial were published in the peer-reviewed journal <a href=\"https:\/\/www.nature.com\/articles\/s41586-023-06063-y\" rel=\"nofollow noopener\" target=\"_blank\"><i><u>Nature<\/u><\/i><\/a>. Trials in other indications are ongoing.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>BNT211 <\/b>is an autologous Claudin-6 (CLDN6)-targeting chimeric antigen receptor (CAR) T cell therapy candidate that is being tested alone and in combination with an investigational CAR-T cell Amplifying RNA Vaccine compound, or CARVac, encoding CLDN6.<\/p>\n<ul>\n<li>A data update from the ongoing Phase 1\/2 clinical trial (<a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04503278\" rel=\"nofollow noopener\" target=\"_blank\"><u>NCT04503278<\/u><\/a>) was provided at the 2023 ASCO Annual Meeting detailing the new dose escalation of CLDN6 CAR-T cells with and without a CLDN6-encoding mRNA vaccine for the treatment of CLDN6-positive relapsed\/refractory solid tumors using an automated manufacturing process. CLDN6 CAR-T cells \u00b1 CLDN6 CARVac showed a moderate safety profile in line with that of manually produced CLDN6 CAR-T cells. Encouraging signs of clinical activity for dose level 1 and 2 were confirmed, including dose-dependent expansion of CAR-T cells demonstrated by an objective response rate (ORR) of 41% in all 17 evaluable patients and an ORR of 75% in patients at dose level 2. Follow-up of treated patients and further enrollment of patients into dose level 2 and 3 are ongoing. After determination of a recommended Phase 2 dose for CLDN6 CAR-T cells, a pivotal trial in germ cell tumors is planned to start in 2024.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>Corporate Update for the Second Quarter 2023 and Key Post Period-End Events<\/b>\n      <\/p>\n<ul>\n<li>In April, BioNTech entered into exclusive license and collaboration agreements with DualityBio to develop, manufacture and commercialize two investigational topoisomerase-1 inhibitor-based ADC assets, BNT323\/DB-1303 and BNT324\/DB-1311. In August 2023, BioNTech signed another agreement with DualityBio to develop, manufacture and commercialize an additional antibody-drug conjugate, DB-1305.<\/li>\n<li>In July, following on a memorandum of understanding announced in January, BioNTech signed a long-term strategic partnership agreement with the UK Government, NHS England and Genomics England Limited with the aim to provide access to personalized treatments for up to 10,000 patients by 2030, either in clinical trials or as authorized treatment. To execute this, BioNTech plans to set up new laboratories in Cambridge with an expected capacity of more than 70 highly skilled scientists as well as a new regional hub for the United Kingdom.<\/li>\n<li>In July, BioNTech also successfully completed its previously announced acquisition of InstaDeep, following the satisfaction of all customary closing conditions. The acquisition supports the Company\u2019s strategy to build world-leading capabilities in Artificial Intelligence (\u201cAI\u201d)-driven drug discovery and development. InstaDeep will operate as a UK-based global subsidiary of BioNTech. The transaction adds approximately 290 highly skilled professionals to BioNTech\u2019s workforce, including teams in AI, machine learning (\u201cML\u201d), bioengineering, data science, and software development.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>Environmental, Social, and Governance (ESG) <\/b>\n      <\/p>\n<p align=\"justify\">BioNTech was founded out of a responsibility to patients and to society and this is still the vision that drives the Company. It gives grounds for BioNTech\u2019s enhanced responsibility: for translating the Company\u2019s science into the health of people worldwide and democratizing access to innovative medicines, for environmental and climate protection, for respecting human rights and for fostering the full potential of all employees.<\/p>\n<p align=\"justify\">In March 2023, BioNTech published its third ESG report (Sustainability Report 2022). The report highlights the Company\u2019s progress in developing novel medicines and introducing scalable technological innovations. It describes BioNTech\u2019s science-based climate goals (under SBTi review), actions and climate risk management as well as the status of the Companies\u2019 human rights strategy and due diligence. The report addresses diversity, inclusion, equity and belonging, and highlights the importance of BioNTech\u2019s values and culture. <\/p>\n<p align=\"justify\">BioNTech recognizes its responsibility as a corporate citizen and is committed to supporting its local communities and beyond through donations, sponsorships and volunteer activities.<\/p>\n<p align=\"justify\">\n        <b>Upcoming Investor and Analyst Events<\/b>\n      <\/p>\n<ul>\n<li>BioNTech&#8217;s third quarter 2023 financial results and corporate update are scheduled for Monday, November 6, 2023.<\/li>\n<li>BioNTech will host its 2nd Innovation Day on Tuesday, November 7, 2023, in Boston, USA.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>Conference Call and Webcast Information<\/b>\n      <\/p>\n<p align=\"justify\">BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, August 7, 2023, at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the second quarter of 2023.<\/p>\n<p align=\"justify\">To access the live conference call via telephone, please register <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HPpCPVwG2PPEUSAADRDOnqsjuVu70W7p7XCLPwuLyKN0FaE2I7kdHbnkbtq2ZtzctE3m6-mBrdnHyJyC9B-wK6-IFRnZGRgR-znUI_psxb_Lvc5_T26nHPm_jB6HAn8CG84Hn9NZbgcIUQ1yby-arw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>via this link<\/u><\/a>. Once registered, dial-in numbers and a pin number will be provided.<\/p>\n<p align=\"justify\">The slide presentation and audio of the webcast will be available <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HPpCPVwG2PPEUSAADRDOnvc0B94T2LGVs6axDn6Arp9dY_fjV9MsB7MwnrvJY0ozxCjdhxgwwKrHo6LBfGI1lAhigYAa212Mt6ruTrzyJAb1IiXOeLeSuEiuolD60tBO\" rel=\"nofollow noopener\" target=\"_blank\"><u>via this link<\/u><\/a>.<\/p>\n<p align=\"justify\">Participants may also access the slides and the webcast of the conference call via the \u201cEvents &amp; Presentations\u201d page of the Investor Relations section of the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ylc2lem7k_m7IpN5JQC-C7B9oJHybJB7kJ2OKvmrB9ufFKICHjRxq-4837bOiI-V_a8KR81HOcwjR8pLqOjC_kEW3kgdLEJD1mYHtaGqP18=\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/biontech.com<\/u><\/a>. A replay of the webcast will be available shortly after the conclusion of the call and archived on the Company\u2019s website for 30 days following the call.<\/p>\n<p align=\"justify\">\n        <b>About BioNTech<\/b><br \/>\n        <br \/>Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, OncoC4, Regeneron, Sanofi, and Pfizer.<\/p>\n<p align=\"justify\">For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tZcg9UH-6d9IlnREMIcr0Q9GLykbRSugCvRweD_66Ak-OSr7RhKS_9gO_K-oZzO74CjHvzi7aVaDiIqVfvmCf5H4MOJ471wd0GpKvI4XeUk=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.BioNTech.com<\/u><\/a><\/p>\n<p align=\"justify\">\n        <b>Forward-Looking Statements<\/b><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech&#8217;s expected revenues and net profit related to sales of BioNTech&#8217;s COVID-19 vaccine, referred to as COMIRNATY\u00a0where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech&#8217;s collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech&#8217;s partners; the rate and degree of market acceptance of BioNTech&#8217;s COVID-19 vaccine and, if approved, BioNTech&#8217;s investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech&#8217;s research and development programs, including those relating to additional formulations of BioNTech&#8217;s COVID-19 vaccine, and BioNTech&#8217;s current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work and the availability of results; our expectations with respect to our intellectual property;\u00a0 the\u00a0 impact of the Company\u2019s acquisition of InstaDeep Ltd. and collaboration and licensing agreements with OncoC4, Inc., Duality Biologics (Suzhou) Co. Ltd. and others; the development of sustainable vaccine production and supply solutions, and the nature and feasibility of these solutions; and BioNTech&#8217;s estimates of commercial and other revenues, cost of sales, research and development expenses, sales and marketing expenses, general and administrative expenses, capital expenditures, income taxes, net profit, cash, cash equivalents and security investments, shares outstanding and cash outflows and share consideration. In some cases, forward-looking statements can be identified by terminology such as \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201caims,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech\u2019s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: BioNTech&#8217;s pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after BioNTech&#8217;s initial sales to national governments;\u00a0the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; competition from other COVID-19 vaccines or related to BioNTech&#8217;s other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the timing of and BioNTech&#8217;s ability to obtain and maintain regulatory approval for BioNTech&#8217;s product candidates; the ability of BioNTech\u2019s COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech&#8217;s and its counterparties\u2019\u00a0ability to manage and source necessary energy resources; BioNTech&#8217;s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech&#8217;s third-party collaborators to continue research and development activities relating to BioNTech&#8217;s development candidates and investigational medicines; the impact of the COVID-19 pandemic on BioNTech&#8217;s development programs, supply chain, collaborators and financial performance; unforeseen safety issues and potential claims that are alleged to arise from the use of BioNTech&#8217;s COVID-19 vaccine and other products and product candidates developed or manufactured by BioNTech; BioNTech&#8217;s and its collaborators\u2019 ability to commercialize and market BioNTech&#8217;s COVID-19 vaccine and, if approved, its product candidates; BioNTech&#8217;s ability to manage its development and expansion; regulatory developments in the United States and other countries; BioNTech&#8217;s ability to effectively scale BioNTech&#8217;s production capabilities and manufacture BioNTech&#8217;s products, including BioNTech&#8217;s target COVID-19 vaccine production levels, and BioNTech&#8217;s product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading \u201cRisk Factors\u201d in BioNTech&#8217;s Report on Form 6-K for the period ended June 30, 2023 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tZcg9UH-6d9IlnREMIcr0STiemNmDdAjavi2ZNvo5OxmUZZi_xQ6-RyD1Mft4p9CrKw0mBLw_bKNO-8Df_CJbw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.sec.gov<\/u><\/a>. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech\u2019s current expectations and speak only as of the date hereof.<\/p>\n<p align=\"justify\">\n        <b>Contacts<\/b>\n      <\/p>\n<p>\n        <b>Investor Relations<\/b><br \/>\n        <br \/>Victoria Meissner, M.D.<br \/>+1 617 528 8293<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nx01BRfk-1-rl-sD5HnYLeMCbm4HMVrWM0gLuqoHZRBD633vqD_UWbGpcDGetOp_G2kBhDN0cQON_-V5PovUHBRG4owmSvkqsqdZEUNpoFg=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Investors@biontech.de<\/u><\/a><\/p>\n<p>\n        <b>Media Relations<\/b><br \/>\n        <br \/>Jasmina Alatovic<br \/>+49 (0)6131 9084 1513<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_Zi6uxnvxLTw8b46bRR_mLiUk2Jv79GTDCg0e6n-OsceXr7lyjW8t57CuzEIhbDXj_Xp2r-oAy6csiI-UYWkqRWuMJS7iOhObtSeL8u1PUSSY4wN4F8UqFNZ414ceEtvyotnpkLqBSmO8Dk_uc-8F4FqIj9xYs9nnswXTLxV7To_1J_aQdW5G35oTnZBUmyIIFOo7o5BYnaEwhUBw3lWYRGUOpaQyZmTQuC1os2flQC5Si5_AEFfHB5yY4HxIlUuLj8tVDx5D5BibCRWI2Lofw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Media@biontech.de<\/u><\/a><\/p>\n<p align=\"center\">\n        <b>Interim Consolidated Statements of Profit or Loss<\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:306px;vertical-align: bottom\">    \u00a0    <\/td>\n<td colspan=\"2\" style=\"width:150px;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle\">\n            <b>Three months ended <\/b><br \/>\n            <br \/>\n            <b>June 30, <\/b>\n          <\/td>\n<td colspan=\"2\" style=\"width:150px;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle;vertical-align: bottom;text-align: center;vertical-align: middle\">\n            <b>Six months ended <\/b><br \/>\n            <br \/>\n            <b>June 30, <\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">    \u00a0    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">\n            <b>2023<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">\n            <b>2022<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">\n            <b>2023<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">\n            <b>2022<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">\n            <i>(in millions \u20ac, except per share data)<\/i>\n          <\/td>\n<td style=\"width:75px;text-align: center;vertical-align: middle;border-left: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:75px;text-align: center;vertical-align: middle;border-left: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:75px;text-align: center;vertical-align: middle;border-left: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:75px;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px;border-top: solid black 1pt\">    Revenues    <\/td>\n<td style=\"width:75px;border-top: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-top: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-top: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    Commercial revenues    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    166.4    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    3,166.3    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    1,442.9    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    9,528.5    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt\">    Research &amp; development revenues    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    1.3    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    30.2    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    1.8    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    42.6    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px;border-bottom: solid black 1pt\">\n            <b>Total revenues<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>167.7<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>3,196.5<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>1,444.7<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>9,571.1<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    \u00a0    <\/td>\n<td style=\"width:75px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">    Cost of sales    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (162.9)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (764.6)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (258.9)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (2,058.7)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">    Research and development expenses    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (373.4)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (399.6)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (707.4)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (685.4)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">    Sales and marketing expenses    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (18.1)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (17.8)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (30.3)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (32.1)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">    General and administrative expenses     <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (122.7)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (130.0)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (242.1)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (220.8)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">    Other operating expenses     <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (74.2)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (240.7)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (192.3)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (309.5)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">    Other operating income     <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    20.3    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    565.8    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    77.4    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    697.7    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px;border-top: solid black 1pt;border-bottom: solid black 1pt\">\n            <b>Operating income \/ (loss)<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>(563.3)<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>2,209.6<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>91.1<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>6,962.3<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">    \u00a0    <\/td>\n<td style=\"width:75px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">    Finance income    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    152.4    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    115.5    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    208.9    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    387.6    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">    Finance expenses    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (1.3)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (5.8)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (4.5)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (12.5)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px;border-top: solid black 1pt;border-bottom: solid black 1pt\">\n            <b>Profit \/ (loss) before tax<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>(412.2)<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>2,319.3<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>295.5<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>7,337.4<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">    \u00a0    <\/td>\n<td style=\"width:75px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px;border-bottom: solid black 1pt\">    Income taxes    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    221.8    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (647.3)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    16.3    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (1,966.6)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">\n            <b>Profit \/ (Loss) for the period<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">\n            <b>(190.4)<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">\n            <b>1,672.0<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">\n            <b>311.8<\/b>\n          <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">\n            <b>5,370.8<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px;border-top: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-top: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-top: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-top: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">\n            <b>Earnings per share<\/b>\n          <\/td>\n<td style=\"width:75px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:75px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px\">    Basic profit \/ (loss) for the period per share    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (0.79)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    6.86    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    1.29    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    22.00    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:306px;border-bottom: solid black 1pt\">    Diluted profit \/ (loss) for the period per share    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (0.79)    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    6.45    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    1.28    <\/td>\n<td style=\"width:75px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    20.69    <\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <b>Interim Consolidated Statements of Financial Position<\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:402px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">\n            <b>June 30, <\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">\n            <b>December 31, <\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;vertical-align: bottom\">\n            <i>(in millions \u20ac)<\/i>\n          <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">\n            <b>2023<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">\n            <b>2022<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-bottom: solid black 1pt\">\n            <b>Assets <\/b>\n          <\/td>\n<td style=\"width:9px;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:95px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">\n            <b>Non-current assets <\/b>\n          <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:95px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Intangible assets     <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    501.4    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    219.7    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Property, plant and equipment     <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    691.1    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    609.2    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Right-of-use assets    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    202.9    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    211.9    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Other financial assets    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    1,374.3    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    80.2    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Other non-financial assets    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    2.5    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    6.5    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-bottom: solid black 1pt\">    Deferred tax assets     <\/td>\n<td style=\"width:9px;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    239.5    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    229.6    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-bottom: solid black 1pt\">\n            <b>Total non-current assets <\/b>\n          <\/td>\n<td style=\"width:9px;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>3,011.7<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>1,357.1<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">\n            <b>Current assets<\/b>\n          <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:95px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Inventories     <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    448.9    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    439.6    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Trade and other receivables     <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    2,657.9    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    7,145.6    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Contract assets     <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    5.9    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    \u2014    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Other financial assets     <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    1,390.7    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    189.4    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Other non-financial assets    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    212.3    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    271.9    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Income tax assets     <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    331.6    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    0.4    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Cash and cash equivalents    <\/td>\n<td style=\"width:9px\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    14,166.6    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    13,875.1    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-top: solid black 1pt;border-bottom: solid black 1pt\">\n            <b>Total current assets <\/b>\n          <\/td>\n<td style=\"width:9px;border-top: solid black 1pt;border-bottom: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>19,213.9<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>21,922.0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-bottom: solid black 1pt\">\n            <b>Total assets<\/b>\n          <\/td>\n<td style=\"width:9px;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>22,225.6<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>23,279.1<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    \u00a0    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:95px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-bottom: solid black 1pt\">\n            <b>Equity and liabilities <\/b>\n          <\/td>\n<td style=\"width:9px;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;border-bottom: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:95px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">\n            <b>Equity <\/b>\n          <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:95px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Share capital    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    248.6    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    248.6    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Capital reserve    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    1,424.4    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    1,828.2    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Treasury shares    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (8.8)    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (5.3)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Retained earnings    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    19,144.8    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    18,833.0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Other reserves     <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (902.5)    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (848.9)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-top: solid black 1pt;border-bottom: solid black 1pt\">\n            <b>Total equity <\/b>\n          <\/td>\n<td style=\"width:9px;border-top: solid black 1pt;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>19,906.5<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>20,055.6<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">\n            <b>Non-current liabilities <\/b>\n          <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:95px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Lease liabilities, loans and borrowings    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    167.1    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    176.2    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Other financial liabilities     <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    6.1    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    6.1    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Income tax liabilities    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    10.4    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Provisions    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    8.6    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    8.6    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Contract liabilities    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    302.1    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    48.4    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Other non-financial liabilities    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    11.7    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    17.0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-bottom: solid black 1pt\">    Deferred tax liabilities    <\/td>\n<td style=\"width:9px;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    4.5    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    6.2    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-bottom: solid black 1pt\">\n            <b>Total non-current liabilities <\/b>\n          <\/td>\n<td style=\"width:9px;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>500.1<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>272.9<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">\n            <b>Current liabilities <\/b>\n          <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:95px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Lease liabilities, loans and borrowings    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    38.6    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    36.0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Trade payables and other payables    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    228.6    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    204.1    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Other financial liabilities     <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    172.5    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    785.1    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Refund liabilities    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    24.4    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Income tax liabilities    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    554.9    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    595.9    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Provisions    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    374.8    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    367.2    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px\">    Contract liabilities    <\/td>\n<td style=\"width:9px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    201.2    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    77.1    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-bottom: solid black 1pt\">    Other non-financial liabilities    <\/td>\n<td style=\"width:9px;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    248.4    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    860.8    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-bottom: solid black 1pt\">\n            <b>Total current liabilities<\/b>\n          <\/td>\n<td style=\"width:9px;border-bottom: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>1,819.0<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>2,950.6<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-bottom: solid black 1pt\">\n            <b>Total liabilities <\/b>\n          <\/td>\n<td style=\"width:9px;border-bottom: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>2,319.1<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>3,223.5<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:402px;border-bottom: solid black 1pt\">\n            <b>Total equity and liabilities <\/b>\n          <\/td>\n<td style=\"width:9px;border-bottom: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>22,225.6<\/b>\n          <\/td>\n<td style=\"width:95px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>23,279.1<\/b>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <b>Interim Consolidated Statements of Cash Flows<\/b>\n      <\/p>\n<p>\n        <br \/> \u00a0<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:346px;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td colspan=\"2\" style=\"width:144px;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle;vertical-align: bottom;text-align: center;vertical-align: middle\">\n            <b>Three months ended <\/b><br \/>\n            <br \/>\n            <b>June 30, <\/b>\n          <\/td>\n<td colspan=\"2\" style=\"width:144px;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle;text-align: center;vertical-align: middle;vertical-align: bottom;text-align: center;vertical-align: middle\">\n            <b>Six months ended <\/b><br \/>\n            <br \/>\n            <b>June 30, <\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    \u00a0    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">\n            <b>2023<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">\n            <b>2022<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">\n            <b>2023<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">\n            <b>2022<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;border-bottom: solid black 1pt\">\n            <i>(in millions \u20ac)<\/i>\n          <\/td>\n<td style=\"width:8px;border-bottom: solid black 1pt;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:72px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:72px;text-align: center;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<td style=\"width:72px;text-align: center;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <i>(unaudited)<\/i>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">\n            <b>Operating activities<\/b>\n          <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt;vertical-align: bottom\">    \u00a0    <\/td>\n<td style=\"width:72px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Profit \/ (Loss) for the period    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (190.4)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    1,672.0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    311.8    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    5,370.8    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;border-bottom: solid black 1pt\">    Income taxes    <\/td>\n<td style=\"width:8px;border-bottom: solid black 1pt;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (221.8)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    647.3    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (16.3)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    1,966.6    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;border-bottom: solid black 1pt\">\n            <b>Profit \/ (Loss) before tax <\/b>\n          <\/td>\n<td style=\"width:8px;border-bottom: solid black 1pt;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>(412.2)<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>2,319.3<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>295.5<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>7,337.4<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Adjustments to reconcile profit before tax to net cash flows:    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    Depreciation and amortization of property, plant, equipment, intangible assets and right-of-use assets    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    31.9    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    33.2    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    63.3    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    60.8    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    Share-based payment expenses    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    13.1    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    14.8    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    21.7    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    25.0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    Net foreign exchange differences    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (397.0)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (344.6)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (343.9)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (338.5)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    Loss on disposal of property, plant and equipment    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    0.1    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    0.2    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    0.3    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    0.2    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    Finance income excluding foreign exchange differences    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (126.6)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (1.5)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (208.9)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (218.8)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    Finance expense excluding foreign exchange differences    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    1.3    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    5.8    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    2.5    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    12.5    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    Movements in government grants    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (3.0)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    \u2014    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    Net loss on derivative instruments at fair value through profit or loss    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    12.0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    86.5    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    88.2    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    84.6    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Working capital adjustments:    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    Decrease in trade and other receivables, contract assets and other assets    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    5,123.6    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    3,174.8    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    6,017.4    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    2,771.3    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    Decrease \/ (increase) in inventories    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (24.8)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    91.6    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (9.3)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    134.8    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: middle;text-align: left;padding-left: 10.0px\">    (Decrease) \/ increase in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    592.7    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (663.1)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (268.9)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    194.4    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Interest received    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    42.5    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    1.5    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    96.1    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    2.2    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Interest paid    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (1.3)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (5.8)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (2.5)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (12.2)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Income tax paid    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (437.3)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (791.4)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (1,282.2)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (2,081.4)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;border-bottom: solid black 1pt\">    Share-based payments    <\/td>\n<td style=\"width:8px;border-bottom: solid black 1pt;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (31.3)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (2.2)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (757.0)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (3.0)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;border-bottom: solid black 1pt\">\n            <b>Net cash flows from operating activities<\/b>\n          <\/td>\n<td style=\"width:8px;border-bottom: solid black 1pt;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>4,386.7<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>3,919.1<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>3,709.3<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>7,969.3<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    \u00a0    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">\n            <b>Investing activities<\/b>\n          <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Purchase of property, plant and equipment    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (67.2)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (70.6)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (112.4)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (114.7)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Purchase of intangible assets and right-of-use assets    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (242.1)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (4.8)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (251.7)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (21.5)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Investment in other financial assets    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (1,982.5)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (3.0)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (2,663.1)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (30.0)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;border-bottom: solid black 1pt\">    Proceeds from maturity of other financial assets    <\/td>\n<td style=\"width:8px;border-bottom: solid black 1pt;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    375.2    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;border-bottom: solid black 1pt\">\n            <b>Net cash flows from \/ (used in) investing activities<\/b>\n          <\/td>\n<td style=\"width:8px;border-bottom: solid black 1pt;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>(2,291.8)<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>(78.4)<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>(3,027.2)<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>209.0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    \u00a0    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">\n            <b>Financing activities<\/b>\n          <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Proceeds from issuance of share capital and treasury shares, net of costs    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    110.5    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Proceeds from loans and borrowings    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    0.2    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    0.2    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Repayment of loans and borrowings    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (18.8)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Payments related to lease liabilities    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (9.4)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (10.5)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (18.7)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (21.9)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Share repurchase program    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (154.0)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (286.9)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    (436.0)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    (286.9)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;border-bottom: solid black 1pt\">    Dividends    <\/td>\n<td style=\"width:8px;border-bottom: solid black 1pt;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (484.3)    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    \u2014    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    (484.3)    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;border-bottom: solid black 1pt\">\n            <b>Net cash flows used in financing activities<\/b>\n          <\/td>\n<td style=\"width:8px;border-bottom: solid black 1pt;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>(163.4)<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>(781.5)<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>(454.7)<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>(701.2)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    \u00a0    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-left: solid black 1pt\">    \u00a0    <\/td>\n<td style=\"width:72px;border-right: solid black 1pt;border-left: solid black 1pt\">    \u00a0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Net increase in cash and cash equivalents    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    1,931.5    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    3,059.2    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    227.4    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    7,477.1    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px\">    Change in cash and cash equivalents resulting from exchange rate differences    <\/td>\n<td style=\"width:8px;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    91.2    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    111.5    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-left: solid black 1pt\">    64.1    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-left: solid black 1pt\">    165.0    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;border-bottom: solid black 1pt\">    Cash and cash equivalents at the beginning of the period    <\/td>\n<td style=\"width:8px;border-bottom: solid black 1pt;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    12,143.9    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    6,164.1    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">    13,875.1    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">    1,692.7    <\/td>\n<\/tr>\n<tr>\n<td style=\"width:346px;border-bottom: solid black 1pt\">\n            <b>Cash and cash equivalents as of June 30<\/b>\n          <\/td>\n<td style=\"width:8px;border-bottom: solid black 1pt;vertical-align: top\">    \u00a0    <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>14,166.6<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>9,334.8<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>14,166.6<\/b>\n          <\/td>\n<td style=\"width:72px;text-align: right;vertical-align: middle;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt\">\n            <b>9,334.8<\/b>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        <br \/>  \u00a0<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzQwMCM0MDE1OTE2NDQjMjAwMDk4NQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/Mzc4NTA3MmQtYmY1Ni00MGUxLWFjNzEtNWRkZmY0NjI1ZWE4LTEwMTI1NTg=\/tiny\/BioNTech-SE.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Significant pipeline advancement highlighted by the initiation of BNT316\/ONC-392 Phase 3 pivotal trial and multiple trials planned to start across the oncology portfolio Positive data updates across multiple technology platforms including ADC candidate BNT323\/DB-1303, anti-CTLA4 monoclonal antibody candidate BNT316\/ONC-392 and CAR-T candidate BNT211 Preparation for launch of Omicron XBB.1.5-adapted monovalent COVID-19 vaccine as recommended by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and other health authorities; deliveries expected to start as early as September, subject to regulatory approval Reiterates COVID-19 vaccine revenue guidance of approximately \u20ac5 billion in 2023 First half1 of 2023 revenues of \u20ac1.4\u00a0billion2, net profit of \u20ac311.8 million and fully diluted earnings per share of \u20ac1.28 ($1.383) Conference call and webcast scheduled for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-775761","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Significant pipeline advancement highlighted by the initiation of BNT316\/ONC-392 Phase 3 pivotal trial and multiple trials planned to start across the oncology portfolio Positive data updates across multiple technology platforms including ADC candidate BNT323\/DB-1303, anti-CTLA4 monoclonal antibody candidate BNT316\/ONC-392 and CAR-T candidate BNT211 Preparation for launch of Omicron XBB.1.5-adapted monovalent COVID-19 vaccine as recommended by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and other health authorities; deliveries expected to start as early as September, subject to regulatory approval Reiterates COVID-19 vaccine revenue guidance of approximately \u20ac5 billion in 2023 First half1 of 2023 revenues of \u20ac1.4\u00a0billion2, net profit of \u20ac311.8 million and fully diluted earnings per share of \u20ac1.28 ($1.383) Conference call and webcast scheduled for &hellip; Continue reading &quot;BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-07T10:03:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzQwMCM0MDE1OTE2NDQjMjAwMDk4NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"22 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update\",\"datePublished\":\"2023-08-07T10:03:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\\\/\"},\"wordCount\":4419,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzMzQwMCM0MDE1OTE2NDQjMjAwMDk4NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\\\/\",\"name\":\"BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzMzQwMCM0MDE1OTE2NDQjMjAwMDk4NQ==\",\"datePublished\":\"2023-08-07T10:03:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzMzQwMCM0MDE1OTE2NDQjMjAwMDk4NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgzMzQwMCM0MDE1OTE2NDQjMjAwMDk4NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update - Market Newsdesk","og_description":"Significant pipeline advancement highlighted by the initiation of BNT316\/ONC-392 Phase 3 pivotal trial and multiple trials planned to start across the oncology portfolio Positive data updates across multiple technology platforms including ADC candidate BNT323\/DB-1303, anti-CTLA4 monoclonal antibody candidate BNT316\/ONC-392 and CAR-T candidate BNT211 Preparation for launch of Omicron XBB.1.5-adapted monovalent COVID-19 vaccine as recommended by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and other health authorities; deliveries expected to start as early as September, subject to regulatory approval Reiterates COVID-19 vaccine revenue guidance of approximately \u20ac5 billion in 2023 First half1 of 2023 revenues of \u20ac1.4\u00a0billion2, net profit of \u20ac311.8 million and fully diluted earnings per share of \u20ac1.28 ($1.383) Conference call and webcast scheduled for &hellip; Continue reading \"BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-07T10:03:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzQwMCM0MDE1OTE2NDQjMjAwMDk4NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"22 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update","datePublished":"2023-08-07T10:03:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/"},"wordCount":4419,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzQwMCM0MDE1OTE2NDQjMjAwMDk4NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/","name":"BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzQwMCM0MDE1OTE2NDQjMjAwMDk4NQ==","datePublished":"2023-08-07T10:03:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzQwMCM0MDE1OTE2NDQjMjAwMDk4NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgzMzQwMCM0MDE1OTE2NDQjMjAwMDk4NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biontech-announces-second-quarter-2023-financial-results-and-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/775761","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=775761"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/775761\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=775761"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=775761"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=775761"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}